Immediate Oxygen Therapy Required - Sacubitril/Valsartan is NOT the Priority
This patient requires immediate high-flow oxygen therapy via reservoir mask at 15 L/min to correct life-threatening hypoxemia (SpO₂ 78-86%), and sacubitril/valsartan should NOT be initiated during acute hypoxemic crisis. 1
Critical Immediate Management
Step 1: Emergency Oxygen Administration
With SpO₂ fluctuating between 78-86% on room air, this represents severe acute hypoxemia requiring urgent intervention:
- Start reservoir mask at 15 L/min immediately 1
- Target SpO₂ of 94-98% (unless patient has COPD or risk factors for hypercapnia, then target 88-92%) 1
- Monitor continuously until stable 1
Critical pitfall: Do not delay oxygen therapy while determining the underlying cause. The BTS guideline explicitly states that for any acute hypoxemia with SpO₂ below 85%, reservoir mask at 15 L/min is the initial treatment regardless of etiology 1
Step 2: Assess for Heart Failure vs Other Causes
Since you're considering sacubitril/valsartan, this suggests possible acute heart failure:
If acute heart failure with pulmonary edema:
- Consider CPAP or NIV (BiPAP) in addition to oxygen 1
- This is specifically recommended for pulmonary edema cases 1
- BiPAP can improve oxygenation while reducing preload and afterload
If NOT heart failure:
- Continue reservoir mask oxygen
- Investigate other causes (pneumonia, PE, pneumothorax, etc.)
- Adjust oxygen delivery device based on response
Step 3: Obtain Arterial Blood Gas
- Essential within 1 hour of requiring increased oxygen 1
- Check for hypercapnia (especially if COPD risk factors present)
- Assess acid-base status and guide further management
Why NOT Start Sacubitril/Valsartan Now
Sacubitril/valsartan is absolutely contraindicated in this acute setting for multiple reasons:
Hypotension Risk: The drug causes significant blood pressure lowering 2. A patient with SpO₂ 78-86% likely has compromised hemodynamics, and adding a vasodilator could precipitate cardiovascular collapse.
Not for Acute Decompensation: Sacubitril/valsartan is indicated for chronic heart failure management, not acute respiratory failure 2. The FDA label and clinical trials (PARADIGM-HF, PARAGON-HF) studied stable outpatients, not acutely hypoxemic patients 2.
Requires Hemodynamic Stability: The 2025 HFA consensus explicitly states that patients with low blood pressure or acute decompensation need stabilization FIRST before considering sacubitril/valsartan 3. Volume status must be optimized and acute issues resolved.
Run-in Period Required: Even in stable patients, sacubitril/valsartan requires careful titration starting at low doses 2. During clinical trials, 10.4% of patients discontinued during the run-in period due to adverse events including hypotension and renal dysfunction 2.
Correct Sequence of Management
Immediate (Minutes to Hours):
- Reservoir mask 15 L/min oxygen 1
- Consider BiPAP if heart failure suspected 1
- Obtain ABG
- Senior medical assessment
- Treat underlying cause (diuretics for heart failure, antibiotics for pneumonia, etc.)
Once Stabilized (Days to Weeks):
- If confirmed heart failure with reduced ejection fraction
- After achieving euvolemia and hemodynamic stability
- After optimizing diuretics and achieving adequate blood pressure
- THEN consider initiating sacubitril/valsartan at low dose 3, 2
Common Pitfall: Starting neurohormonal antagonists (ACE inhibitors, ARBs, sacubitril/valsartan) during acute decompensated heart failure before achieving stability leads to hypotension, worsening renal function, and poor outcomes 3.
Escalation Criteria
If SpO₂ remains <90% despite reservoir mask at 15 L/min:
- Consider high-flow nasal cannula (HFNC) 4
- Prepare for possible intubation
- Request critical care support urgently 5
- Do NOT delay escalation waiting for improvement
The priority is oxygenation first, hemodynamic optimization second, and chronic heart failure medications only after stabilization.